BLX-1002, a novel thiazolidinedione with no PPAR affinity, stimulates AMP- Activated protein kinase activity, raises cytosolic Ca 2+, and enhances glucose- Stimulated insulin secretion in a PI3K-dependent manner

American Journal of Physiology - Cell Physiology

Volumn 296, Issue 2, 2009, Pages

  Zhang, Fan ^a   Dey, Deben ^b   Bränstrom, Robert ^c   Forsberg, Lars ^c   Lu, Ming ^c   Zhang, Qimin ^a   Sjöholm, Åke ^a  

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

^b Bexel Pharmaceuticals Inc   (United States)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adenosine 5 Monophosphate; Calcium; Diabetes; Islet; Phosphatidylinositol 3 kinase

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ADENOSINE TRIPHOSPHATE; BLX 1002; CALCIUM; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; POTASSIUM CHANNEL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; THAPSIGARGIN; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL; WORTMANNIN;

ANIMAL CELL; ARTICLE; BIOLOGICAL ACTIVITY; CALCIUM MOBILIZATION; CELL FUNCTION; CELL STIMULATION; CONTROLLED STUDY; CYTOPLASM; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; INSULIN RELEASE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RECEPTOR AFFINITY; STIMULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CALCIUM; CELLS, CULTURED; CYTOSOL; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME ACTIVATION; GLUCOSE; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; KATP CHANNELS; MICE; MICE, INBRED STRAINS; NADP; OBESITY; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PROCETOFEN; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; TIME FACTORS; TISSUE CULTURE TECHNIQUES; UP-REGULATION;

EID: 60849119549     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00444.2008     Document Type: Article

References (61)

1. Akkan AG, Malaisse WJ. Insulinotropic action of AICA riboside. I. Insulin release by isolated islets and the perfused pancreas. Diabetes Res 25: 13-23, 1994.
2. Alter CA, Wolf BA. Identification of phosphatidylinositol 3,4,5-trisphos- phate in pancreatic islets and insulin-secreting beta-cells. Biochem Biophys Res Commun 208: 190-197, 1995.
3. Ashcroft SJ. Protein phosphorylation and beta-cell function. Diabetologia 37, Suppl 2: S21-S29, 1994.
4. Bell GI, Polonsky KS. Diabetes mellitus and genetically programmed defects in beta-cell function. Nature 414:788-791, 2001.
5. 2+, and metabolism for plasma insulin oscillations. Diabetes 51, Suppl 1: S171-S176, 2002.
6. Combettes MM. GLP-1 and type 2 diabetes: physiology and new clinical advances. Curr Opin Pharmacol 6: 598-605, 2006.
7. Da Silva Xavier G, Leclerc I, Salt IP, Doiron B, Hardie DG, Kahn A, Rutter GA. Role of AMP-activated protein kinase in the regulation by glucose of islet beta cell gene expression. Proc Natl Acad Sci USA 97: 4023-4028, 2000.
8. Da Silva Xavier G, Leclerc I, Varadi A, Tsuboi T, Moule SK, Rutter GA. Role for AMP-activated protein kinase in glucose-stimulated insulin secretion and preproinsulin gene expression. Biochem J 371: 761-774, 2003.
9. Da Silva Xavier G, Varadi A, Ainscow EK, Rutter GA. Regulation of gene expression by glucose in pancreatic beta -cells (MIN6) via insulin secretion and activation of phosphatidylinositol 3′-kinase. J Biol Chem 275: 36269-36277, 2000.
10. Davis BJ, Xie Z, Viollet B, Zou MH. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes 55: 496 -505, 2006.
11. De Camilli P, Emr SD, McPherson PS, Novick P. Phosphoinositides as regulators in membrane traffic. Science 271: 1533-1539, 1996.
12. Dey DGA, Pandey B, Nag A, Agarwal SK, Nag B. A non adipogenic compound BLX-1002 induces glucose uptake in 3T3-L1 cells and has strong anti-hyperglycemic effect in db/db and ob/ob mice (Abstract), P866. 18th Congress of the International Diabetes Federation, Paris, France, 2003.
13. Dey DPB, Nag A, Neogi P, Nag B. Amino acid conjugated, orally active, novel anti-diabetic compound BLX-1002 has no affinity to PPAR-γ (Abstract). 2020-PO. American Diabetes Association 64th Scientific Sessions, Orange County Convention Center, Orlando, Florida, 2004.
14. Dey DPB, Pandey A, Nag A, Peng I, Chovatia M, Neogi P, Nag B. Amino acid conjugated small molecule BLX-1002 lowers blood glucose in insulin resistant db/db and ob/ob mice and inhibits TNF-α, IL-6 cytokines (Abstract). Am J Hypertens 17: S32, 2004.
15. Ehses JA, Perren A, Eppler E, Ribaux P, Pospisilik JA, Maor-Cahn R, Gueripel X, Ellingsgaard H, Schneider MK, Biollaz G, Fontana A, Reinecke M, Homo-Delarche F, Donath MY. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 56: 2356-2370, 2007.
16. 2+)] elevation signals. Diabetes 51: 87-97, 2002.
17. Gleason CE, Lu D, Witters LA, Newgard CB, Birnbaum MJ. The role of AMPK and mTOR in nutrient sensing in pancreatic beta-cells. J Biol Chem 282:10341-10351, 2007.
18. Grimsby J, Sarabu R, Corbett WL, Haynes NE, Bizzarro FT, Coffey JW, Guertin KR, Hilliard DW, Kester RF, Mahaney PE, Marcus L, Qi L, Spence CL, Tengi J, Magnuson MA, Chu CA, Dvorozniak MT, Matschinsky FM, Grippo JF. Allosteric activators of glucokinase: potential role in diabetes therapy. Science 301: 370-373, 2003.
19. Gul R, Kim SY, Park KH, Kim BJ, Kim SJ, Im MJ, Kim UH. A novel signaling pathway of ADP-ribosyl cyclase activation by angiotensin II in adult rat cardiomyocytes. Am J Physiol Heart Circ Physiol 295: H77-H88, 2008.
20. Hagar RE, Ehrlich BE. Regulation of the type III InsP3 receptor and its role in beta cell function. Cell Mol Life Sci 57: 1938-1949, 2000.
21. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pfl Ugers Arch 391: 85-100, 1981.
22. Hardie DG. AMP-activated protein kinase as a drug target. Annu Rev Pharmacol Toxicol 47: 185-210, 2007.
23. Harrower AD. Comparative tolerability of sulphonylureas in diabetes mellitus. Drug Saf22: 313-320, 2000.
24. Hawley SA, Davison M, Woods A, Davies SP, Beri RK, Carling D, Hardie DG. Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J Biol Chem 271: 27879-27887, 1996.
25. Henquin JC. Pathways in beta-cell stimulus-secretion coupling as targets for therapeutic insulin secretagogues. Diabetes 53, Suppl 3: S48 -S58,2004.
26. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 87:1409 -1439, 2007.
27. 2+ signaling system stimulated by the insulinotropic hormone glucagon-like peptide-1-(7-37). J Biol Chem 274: 14147-14156, 1999.
28. Ito K, Caramori G, Adcock IM. Therapeutic potential of phosphatidyl- inositol 3-kinase inhibitors in inflammatory respiratory disease. J Pharmacol Exp Ther 321: 1-8, 2007.
29. Jeyapalan AS, Orellana RA, Suryawan A, O'Connor PM, Nguyen HV, Escobar J, Frank JW, Davis TA. Glucose stimulates protein synthesis in skeletal muscle of neonatal pigs through an AMPK- and mTOR-independent process. Am J Physiol Endocrinol Metab 293: E595- E603, 2007.
30. 2+ and the ATP/ADP ratio in pancreatic beta-cells at substimulatory glucose. J Biol Chem 278: 40710-40716, 2003.
31. Kahn SE, Halban PA. Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes 46: 1725-1732, 1997.
32. Kefas BA, Cai Y, Ling Z, Heimberg H, Hue L, Pipeleers D, Van de Casteele M. AMP-activated protein kinase can induce apoptosis of insulin-producing MIN6 cells through stimulation of c-Jun-N-terminal kinase. J Mol Endocrinol 30: 151-161, 2003.
33. Kim WH, Lee JW, Suh YH, Lee HJ, Lee SH, Oh YK, Gao B, Jung MH. AICAR potentiates ROS production induced by chronic high glucose: roles of AMPK in pancreatic beta-cell apoptosis. Cell Signal 19:791-805, 2007.
34. Leclerc I, Rutter GA. AMP-activated protein kinase: a new beta-cell glucose sensor?: regulation by amino acids and calcium ions. Diabetes 53, Suppl 3: S67-S74, 2004.
35. LeRoith D. Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. Am J Med 113, Suppl 6A: 3S-11S, 2002.
36. Levetan C. Oral antidiabetic agents in type 2 diabetes. Curr Med Res Opin 23: 945-952, 2007.
37. Li LX, MacDonald PE, Ahn DS, Oudit GY, Backx PH, Brubaker PL. Role of phosphatidylinositol 3-kinasegamma in the beta-cell: interactions with glucagon-like peptide-1. Endocrinology 147: 3318 -3325, 2006.
38. Long YC, Barnes BR, Mahlapuu M, Steiler TL, Martinsson S, Leng Y, Wallberg-Henriksson H, Andersson L, Zierath JR. Role of AMP- activated protein kinase in the coordinated expression of genes controlling glucose and lipid metabolism in mouse white skeletal muscle. Diabetolo-gia 48: 2354-2364, 2005.
39. MacDonald PE, Joseph JW, Yau D, Diao J, Asghar Z, Dai F, Oudit GY, Patel MM, Backx PH, Wheeler MB. Impaired glucose-stimulated insulin secretion, enhanced intraperitoneal insulin tolerance, and increased beta-cell mass in mice lacking the p110gamma isoform of phosphoinosi- tide 3-kinase. Endocrinology 145: 4078-4083, 2004.
40. McDowell SA, McCall E, Matter WF, Estridge TB, Vlahos CJ. Phosphoinositide 3-kinase regulates excitation-contraction coupling in neonatal cardiomyocytes. Am J Physiol Heart Circ Physiol 286: H796 -H805, 2004.
41. Nag ACM, Peng I, Moon H, Pandey B, Gutala S, Neogi P, Nag B, Dey D. Glucose lowering effect of BLX-1002 in non obese diabetic (NOD) and streptotozotocin (STZ) induced diabetic mice (Abstract) 665-P. American Diabetes Association 64th Scientific Sessions, Orange County Convention Center, Orlando, Florida, 2004.
42. 2+ release in pancreatic beta-cells. Biochem J 248: 329-336, 1987.
43. Porksen N. The in vivo regulation of pulsatile insulin secretion. Diabe-tologia 45: 3-20, 2002.
44. Rameh LE, Cantley LC. The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem 274: 8347-8350, 1999.
45. Rasouli N, Kern PA, Reece EA, Elbein SC. Effects of pioglitazone and metformin on beta-cell function in nondiabetic subjects at high risk for type 2 diabetes. Am J Physiol Endocrinol Metab 292: E359-E365, 2007.
46. Richards SK, Parton LE, Leclerc I, Rutter GA, Smith RM. Over- expression of AMP-activated protein kinase impairs pancreatic beta-cell function in vivo. J Endocrinol 187: 225-235, 2005.
47. Rutter GA, Da Silva Xavier G, Leclerc I. Roles of 5′ -AMP-activated protein kinase (AMPK) in mammalian glucose homoeostasis. Biochem J 375: 1-16, 2003.
48. Salt IP, Johnson G, Ashcroft SJ, Hardie DG. AMP-activated protein kinase is activated by low glucose in cell lines derived from pancreatic beta cells, and may regulate insulin release. Biochem J 335: 533-539, 1998.
49. Stoyanov B, Volinia S, Hanck T, Rubio I, Loubtchenkov M, Malek D, Stoyanova S, Vanhaesebroeck B, Dhand R, Nurnberg B, Gierschik, P, Seedorf, K, Hsuan, JJ, Waterfield, MD, Wetzker R. Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. Science 269: 690-693, 1995.
50. Targonsky ED, Dai F, Koshkin V, Karaman GT, Gyulkhandanyan AV, Zhang Y, Chan CB, Wheeler MB. Alpha-lipoic acid regulates AMP-activated protein kinase and inhibits insulin secretion from beta cells. Diabetologia 49:1587-1598, 2006.
51. Viollet B, Andreelli F, Jorgensen SB, Perrin C, Flamez D, Mu J, Wojtaszewski JF, Schuit FC, Birnbaum M, Richter E, Burcelin R, Vaulont S. Physiological role of AMP-activated protein kinase (AMPK): insights from knockout mouse models. Biochem Soc Trans 31:216-219, 2003.
52. Virkamaki A, Ueki K, Kahn CR. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 103: 931-943, 1999.
53. Wang X, Zhou L, Shao L, Qian L, Fu X, Li G, Luo T, Gu Y, Li F, Li J, Zheng S, Luo M. Troglitazone acutely activates AMP-activated protein kinase and inhibits insulin secretion from beta cells. Life Sci 81: 160-165,2007.
54. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D Jr. Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest 74:1318-1328, 1984.
55. Weir GC, Laybutt DR, Kaneto H, Bonner-Weir S, Sharma A. Beta- cell adaptation and decompensation during the progression of diabetes. Diabetes 50, Suppl 1: S154-S159, 2001.
56. Zhang F, Sjoholm K, Zhang Q. Pioglitazone acutely influences glucose- sensitive insulin secretion in normal and diabetic human islets. Biochem Biophys Res Commun 351:750 -755, 2006.
57. 2+ and insulin secretion. Am J Physiol Cell Physiol 291: C466-C475, 2006.
58. Zhang L, He H, Balschi JA. Metformin and phenformin activate AMP- activated protein kinase in the heart by increasing cytosolic AMP concentration. Am J Physiol Heart Circ Physiol 293: H457-H466, 2007.
59. 2+release in insulin-secreting cells by ryanodine receptor tyrosine phosphorylation. Mol Endocrinol 18: 1658-1669, 2004.
60. Zhang Q, Tally M, Larsson O, Kennedy RT, Huang L, Hall K, Berggren PO. Insulin-like growth factor II signaling through the insulinlike growth factor II/mannose-6-phosphate receptor promotes exocytosis in insulin-secreting cells. Proc Natl Acad Sci USA 94: 6232-6237, 1997.
61. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 414: 782-787, 2001.